Tumor-associated antigen recognized by monoclonal antibody A7

The **tumor-associated antigen recognized by monoclonal antibody A7** is an oncofetal protein or glycoprotein expressed on the surface of various human tumors, including colon carcinoma and glioblastoma multiforme. The exact molecular identity of this antigen is not fully defined in the literature provided; it is described primarily through its reactivity with the murine IgG1 monoclonal antibody known as "A7." This target shows preferential expression in tumor tissues compared to normal adult tissues but may also be present during fetal development ("oncofetal" pattern)[5]. Monoclonal antibody A7 binds specifically to this tumor-associated epitope. Studies have shown that both whole IgG1 antibodies and their F(ab')2 fragments localize efficiently to tumors expressing this antigen when tested in xenograft models. PEGylation of these antibodies can alter pharmacokinetics—improving blood retention while reducing uptake in normal organs—and enhance selective delivery to tumors[2][6]. The biological function associated with this target includes roles in cell adhesion, migration, invasion, and possibly metastasis; inhibition via specific antibodies reduces these malignant properties[4]. Therapeutically, targeting this molecule has been explored for drug delivery or direct antitumor effects via immune mechanisms such as ADCC or CDC. However, because the precise biochemical nature remains incompletely characterized ("antigen recognized by mAb A7" rather than a defined gene/protein), it should be flagged as an incomplete/ambiguous entry for structured databases. Notably, there are related but distinct antigens targeted by other "A" series antibodies—such as those recognizing Thomsen–Friedenreich antigens—which may overlap functionally but are not necessarily identical to the original "A7" target described here[3][8]. In summary: This entry refers to a **tumor-specific surface molecule identified only operationally** via binding with monoclonal antibody A7; it is considered a valid therapeutic target experimentally but lacks full molecular definition at present.

Other names

Tumor-associated antigen A7Oncofetal antigen recognized by A7Antigen recognized by monoclonal antibody A7

Antibody-dependent cell-mediated cytotoxicity (ADCC); Complement-dependent cytotoxicity (CDC); Inhibition of tumor cell adhesion, invasion, and migration[4]